XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Acquired in-process research and development charge $ 0 $ 0 $ 500,000 $ 3,087,832
Research and development 2,077,566 739,598 4,946,304 2,511,438
General and administrative 1,970,521 828,464 6,052,556 1,834,645
Loss from operations (4,048,087) (1,568,062) (11,498,860) (7,433,915)
Interest income (expense), net 192,245 (1,261) 219,405 (64,555)
Change in fair value of convertible promissory notes 0 0 0 9,317
Other income 1,532 126,531 297 124,148
Net loss $ (3,854,310) $ (1,442,792) $ (11,279,158) $ (7,365,005)
Net income (loss) per share - basic (in dollars per share) $ (0.24) $ (4.00) $ (0.71) $ (20.74)
Net income (loss) per share - diluted (in dollars per share) $ (0.24) $ (4.00) $ (0.71) $ (20.74)
Weighted average common shares outstanding - basic (in shares) 15,966,053 361,067 15,966,053 355,087
Weighted average common shares outstanding - diluted (in shares) 15,966,053 361,067 15,966,053 355,087